News

Harrow Health Inc. announced it has agreed to purchase the exclusive U.S. commercial rights to 5 ophthalmic drugs from Novartis AG for up to $175 million, the company announced today.

The partnership was formalized at the recent International Conference for Initiatives on Organ and Tissue Donation and Transplantation in Abu Dhabi.

The investigators explained that deficient ophthalmologic care is costly to patients, making the identification of groups not receiving adequate care of vital importance

Under the terms of the agreement, Ocular will pay Titan an upfront licensing fee with the potential for additional payments upon reaching certain milestones.

According to researcher, the treatment offers improved retinal sensitivity, visual function, and mobility.

Ophthalmologist discusses the impact of getting older on patients diagnosed with the disease.

AZR-MD-001 is currently being studied to evaluate the safety, efficacy, and tolerability of the study drug in patients with MGD.

The ocular biomarkers studied showed poor to moderate accuracy for detecting the 2 disorders.

CXL has been proven effective to treat patients with corneal ectasias.

The results represent a major step towards first in-human clinical studies for this program - the first potential therapy for patients with geographic atrophy secondary to AMD that addresses the underlying causes of the disease.

Receiving FDA orphan drug designation allows the company to proceed with plans to advance the development of BRM424, a novel, first-in-class, potential treatment for neurotrophic keratitis.

The Ernest E. Tschannen Eye Institute is dedicated to eye care and sight restoration through technology, pioneering research and eye care clinicians.

According to the company, the NDA is supported by positive phase data demonstrating the rapid reversal of dilated eyes and favorable safety profile in pediatric and adult subjects.

Researchers from the Deutsches Zentrum für Neurodegenerative Erkrankungen and the Center for Regenerative Therapies Dresden at TU Dresden have found that visual cells in the human retina may not simply die in some diseases, but are mechanically transported out of the retina beforehand.

According to researchers, cells within retinal blood vessels are endowed with a previously unappreciated ability to acquire resistance against the damaging effects of hyperglycemia in patients with diabetes mellitus.

SPVN06 is a breakthrough gene therapy approach aimed at stopping or slowing disease progression in patients affected by IRDs and dry age-related macular degeneration (AMD), regardless of their genetic background.

Weigh in on this month's survey question. The poll will be open until December 16, 2022.

OPGx-001 is Opus’ first program to enter clinical evaluation and is designed to address vision loss due to mutations in the LCA5 gene, which causes one of the most severe forms of early-onset blinding disease Leber congenital amaurosis.

In an effort to educate the public on GA, Prevent Blindness has created a variety of resources for patients in English and Spanish.

Aflibercept and bevacizumab are the two most frequently used therapies for the treatment of wet AMD.

According to the company, the facility will serve as a hub of the EVO Lens-Based Experience for ophthalmic surgeons, staff and healthcare practitioners.

Discovery CORE and its AI models have been designed to accelerate data analysis and help clinical and academic researchers collaborate more efficiently in real time with their peers on medical and imaging datasets.

In a two-decade career as a researcher at Johnson & Johnson Surgical Vision, Piers has been a part of teams at the forefront of a number of innovations in IOLs. She discusses her career and the outlook for research and development in ophthalmology.

Despite the latest advances in anti-VEGF therapy, a small group of patients do not achieve improved vision. Ophthalmologists are looking for options.

According to physicians, patients who do not undergo second procedure are more likely to develop glaucoma.

Re-Vana has demonstrated that its platform can achieve 6 months or greater sustained delivery of an anti-VEGF biologic at therapeutically-relevant levels with high drug loading, controlled burst release, and a favorable degradation profile.

The deal will provide Harrow’s entire formulary compounded ophthalmic products to iOR Partners’ expanding office-based surgery locations across the United States.

The groups invite those attending the annual conference to join them at their event on Monday, January 16, which is free to OWL and WIO members.

According to investigators, the risk for the development of dry eye disease is greater in postmenopausal women compared with those who have not reached menopause as a result of hormonal dysregulation of the ocular secretory glands.